Technology evaluation: lerdelimumab, Cambridge Antibody Technology.

Abstract

Cambridge Antibody Technology is developing lerdelimumab (CAT-152), the lead in a series of human anti-TGF beta 2 antibodies, for its potential in preventing post-operative scarring in patients undergoing surgery for glaucoma (trabulectomy). It also has potential for the treatment of fibrosis, cataract, retinopathy and connective tissue disease.

• Authors: M Francesca Cordeiro
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 2 Pg. 199-203 (Apr 2003) ISSN: 1464-8431 [Print] England
• PMID: 12772512 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• TGFB2 protein, human
• Transforming Growth Factor beta
• Transforming Growth Factor beta2
• Lerdelimumab

Topics

• Antibodies, Monoclonal (biosynthesis, pharmacology)
• Antibodies, Monoclonal, Humanized
• Cicatrix (prevention & control)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Humans
• Transforming Growth Factor beta (antagonists & inhibitors)
• Transforming Growth Factor beta2